AR and prostate carcinoma: Notably, only a subset of AR enhancers were co-occupied by p300 in prostate cancer cells, which was deterministic of stronger transcriptional activation, evidenced both by higher accessibility and subsequent recruitment of the Mediator and Pol II complexes.